Skip to main content
. 2016 Apr 26;107(5):590–600. doi: 10.1111/cas.12919

Table 3.

Immune responses

Pt no. Dose of KRM‐10 (mg) HLA type HLA matching peptides or KRM10 CTL response (pg/mL) IgG response (FIU) Response OS(m)
Prevaccination Post third† Post sixth† Prevaccination Post third† Post sixth†
L1‐1 10 A33 WHSC2‐103 0 0 0 0 0 0 SD 13.9
SART3‐734 0 0 0 159 147 156
Lck‐90 0 28 0 0 0 0
SART3‐109 0 18 0 0 0 0
KRM‐10 0 22 0 ND ND ND
L1‐2 10 A2/A24 SART2‐302 0 0 0 42 58 92 PD 8.7
Lck‐246 0 0 0 0 0 0
WHSC2‐103 0 0 0 0 0 0
HNRPL‐140 0 0 0 0 0 0
EGFR‐800 0 0 0 0 0 0
SART3‐109 0 0 0 0 0 0
Lck‐488 0 0 0 0 0 0
MRPP3‐503 0 0 227 0 0 0
KRM‐10 0 0 260 ND ND ND
L1‐3 10 A11/A31 WHSC2‐103 0 0 0 0 0 0 PD 2.5
SART3‐734 0 0 0 5939 3685 2456
Lck‐90 0 0 0 0 0 0
SART3‐109 0 0 0 0 0 0
KRM‐10 0 0 0 ND ND ND
L1‐4 10 A2/A24 SART3‐302 0 0 0 0 0 0 SD 20.1
Lck‐246 0 0 0 0 0 0
WHSC2‐103 0 0 0 0 0 0
HNRPL‐140 0 0 0 0 0 0
EGFR‐800 0 0 0 0 0 0
SART3‐109 0 0 0 0 0 0
Lck‐488 0 0 0 0 0 0
MRP3‐503 0 0 33 0 0 0
KRM‐10 0 0 0 ND ND ND
L1‐5 10 A24 EGFR‐800 0 0 0 0 0 0 PD 7.6
SART3‐109 0 0 0 0 0 0
Lck‐488 0 0 0 0 0 0
MRP3‐503 0 0 0 0 0 0
KRM‐10 0 0 0 ND ND ND
L1‐6 10 A24/A26 EGFR‐800 0 0 0 0 0 0 PD 3.0
SART3‐109 0 0 0 0 21 25
Lck‐488 20 0 0 74 130 123
MRP3‐503 0 74 42 111 141 144
WHSC2‐103 0 0 0 0 10 0
KRM‐10 0 59 30 ND ND ND
L2‐1 20 A3/A33 WHSC2‐103 0 0 32 0 0 0 PD 7.6
SART3‐734 0 0 131 22 44 18
Lck‐90 26 0 0 0 0 0
SART3‐109 0 0 0 0 0 1090
KRM‐10 0 241 148 ND ND ND
L2‐2 20 A2 SART3‐302 0 0 – 20 22 – PD 3.4
Lck‐246 0 0 – 0 0 –
WHSC2‐103 0 0 – 0 0 –
HNRPL‐140 0 0 – 0 0 –
KRM‐10 0 0 – ND ND –
L2‐3 20 A31 WHSC2‐103 0 0 0 0 14 19 PD 9.8
SART3‐734 0 0 0 0 36 36
Lck‐90 0 0 0 0 16 41
SART3‐109 0 0 0 0 0 24
KRM‐10 0 0 0 ND ND ND
L2‐4 20 A2/A33 SART3‐302 0 0 0 0 0 0 SD 5.1
Lck‐246 0 0 0 0 0 0
WHSC2‐103 22 0 0 15 14 0
HNRPL‐140 0 0 24 27 20 0
SART3‐734 0 0 0 14 11 0
Lck‐90 0 0 0 32 27 135
SART3‐109 0 0 0 14 0 0
KRM‐10 0 0 0 ND ND ND
L2‐5 20 A11 SART3‐302 0 0 0 1682 1595 1088 PD 4.0
Lck‐246 0 0 0 16 11 22
WHSC2‐103 0 0 0 24 19 23
HNRPL‐140 0 20 16 20 15 16
EGFR‐800 0 0 0 13 11 11
SART3‐109 0 0 0 20 12 23
Lck‐488 0 82 0 74 62 61
MRP3‐503 0 131 134 13 10 148
KRM‐10 0 194 177 ND ND ND
L2‐6 20 A24 EGFR‐800 0 0 – 77 73 – PD 1.4
SART3‐109 0 0 – 75 79 –
Lck‐488 0 59 – 429 410 –
MRP3‐503 0 0 – 37 39 –
KRM‐10 0 0 – ND ND –
L2‐7 20 A11/A31 WHSC2‐103 0 0 0 18 14 13 SD 19.9
SART3‐734 0 0 0 8125 8454 8639
Lck‐90 0 0 0 18 17 22
SART3‐109 0 0 0 16 14 14
KRM‐10 0 31 0 ND ND ND
L2‐8 20 A24 EGFR‐800 0 0 0 0 0 0 PD 6.6
SART3‐109 0 0 0 0 0 0
Lck‐488 0 0 0 42 34 30
MRP3‐503 0 0 42 0 0 0
KRM‐10 0 0 57 ND ND ND
L3‐1 30 A2/A31 SART3‐302 0 0 0 273 243 24947 PD 6.2
Lck‐246 0 0 0 0 0 0
WHSC2‐103 0 0 0 12 10 11
HNRPL‐140 0 0 0 11 9 10
SART3‐734 0 0 0 57 43 80
Lck‐90 0 0 0 24 21 566
SART3‐109 0 0 0 10 0 10
KRM‐10 0 0 0 ND ND ND
L3‐2 30 A26/A31 WHSC2‐103 0 82 0 0 0 0 PD 3.7
SART3‐109 0 0 0 0 10 11
SART3‐734 0 0 0 1206 975 454
Lck‐90 0 0 0 23 30 565
KRM‐10 0 0 0 ND ND ND
L3‐3 30 A2/A24 SART3‐302 0 0 0 1337 1715 814 PD 12.8
Lck‐246 0 0 0 19 20 11
WHSC2‐103 0 0 0 24 26 20
HNRPL‐140 91 0 0 22 26 18
EGFR‐800 0 0 0 18 17 14
SART3‐109 0 0 0 21 26 19
Lck‐488 0 0 0 98 108 93
MRP3‐503 0 0 0 15 18 12
KRM‐10 0 0 0 ND ND ND
L3‐4 30 A24/A33 EGFR‐800 0 0 84 0 0 0 PD 10.2
SART3‐109 0 0 0 0 0 0
Lck‐488 0 0 0 18 11 15
MRP3‐503 0 0 0 0 0 0
WHSC2‐103 0 0 0 17 11 11
SART3‐734 0 0 0 3049 2124 3182
Lck‐90 0 0 0 0 0 0
KRM‐10 0 0 0 ND ND ND
L3‐5 30 A24/A26 EGFR‐800 0 0 0 0 0 0 SD 16.6
SART3‐109 0 0 0 932 833 480
Lck‐488 0 0 0 743 652 405
MRP3‐503 0 0 0 643 560 320
WHSC2‐103 0 0 0 74 61 0
KRM‐10 0 0 0 ND ND ND
L3‐6 30 A26/A31 NA NA NA NA NA NA PD 6.1
L3‐7 30 A11 WHSC2‐103 0 0 0 19 20 21 PD 10.8
SART3‐734 0 0 0 1042 1010 1003
Lck‐90 0 12 0 22 22 23
SART3‐109 0 0 0 0 0 11
KRM‐10 0 0 0 ND ND ND
a

A blood test was performed after the third/sixth vaccination or disease progression, whichever occurred first. Pt no., patient number; OS(m), overall survival (months); SD, stable disease; PD, progressive disease; CTL, cytotoxic T lymphocytes; FIU, fluorescent intensity units; ND, not detected; NA, not available. –, Cases with the dashes had no post sixth sample.